Evidence map›Paper›PMID 34011405›Full record

ArticleBreast cancer research : BCR2021

Novel mechanism for OSM-promoted extracellular matrix remodeling in breast cancer: LOXL2 upregulation and subsequent ECM alignment.

Simion C Dinca, Daniel Greiner, Keren Weidenfeld, Laura Bond, Dalit Barkan, Cheryl L Jorcyk

Open access · goldAbstract read
In one paragraph

Article in Breast cancer research : BCR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Liver Kinase B1 in CD11cAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. TME-Related Biomimetic Strategies Against Cancer.International journal of nanomedicine · 2024
    Review
  16. Exploring the multifaceted role of obesity in breast cancer progression.Frontiers in cell and developmental biology · 2024
    Review
  17. Article
  18. Role of oncostatin-M in ECM remodeling and plaque vulnerability.Molecular and cellular biochemistry · 2023
    Review
  19. Review
  20. LOXL2 in Cancer: A Two-Decade Perspective.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Simion C DincaBiomolecular Sciences Graduate Program, Boise State University, 1910 University Drive, MS1515, Boise, ID, 83725, USA.
Daniel GreinerDepartment of Biochemistry, University of Utah School of Medicine, Salt Lake City, UT, 84112, USA.
Keren WeidenfeldDepartment of Human Biology and Medical Sciences, University of Haifa, Haifa, Israel.
Laura BondBiomolecular Research Center, Boise State University, 1910 University Drive, MS1515, Boise, ID, 83725, USA.
Dalit BarkanDepartment of Human Biology and Medical Sciences, University of Haifa, Haifa, Israel.
Cheryl L JorcykBiomolecular Sciences Graduate Program, Boise State University, 1910 University Drive, MS1515, Boise, ID, 83725, USA. cjorcyk@boisestate.edu.ORCID 0000-0001-5715-472X
Boise State University · USUniversity of Haifa · IL

Funding

Women's health: interplay of maternal diet and key demographics on neurological health in the rural frontier and remote WestP20GM103408 · NIGMS · UNIVERSITY OF IDAHO · PI Scott A Minnich · 2012 to 2026
$59.8M
Tracking and EvaluationU54GM104944 · NIGMS · UNIVERSITY OF NEVADA LAS VEGAS · PI KUMAR, PARVESH · 2013 to 2023
$39.6M
VPS35 D620N inhibits autophagy through disrupted hyaluronic acid-CD44 signalingP20GM109095 · NIGMS · BOISE STATE UNIVERSITY · PI OXFORD, JULIA THOM · 2014 to 2023
$22.7M
The Southwest Idaho Bridges to the BaccalaureateR25GM123927 · NIGMS · BOISE STATE UNIVERSITY · PI JORCYK, CHERYL LYNN, LYSNE, STEVEN · 2017 to 2021
$1.6M
National Science Foundation 0619737National Science Foundation 0923535NIGMS NIH HHS 1C06RR020533NIGMS NIH HHS P20 GM109095NIGMS NIH HHS R25 GM123927NIGMS NIH HHS U54 GM104944Smylie Family Cancer Fund (US) AR298United States - Israel Binational Science Foundation 2017237
6 · The paper itself

Abstract

backgroundInvasive ductal carcinoma (IDC) is a serious problem for patients as it metastasizes, decreasing 5-year patient survival from > 95 to ~ 27%. The breast tumor microenvironment (TME) is often saturated with proinflammatory cytokines, such as oncostatin M (OSM), which promote epithelial-to-mesenchymal transitions (EMT) in IDC and increased metastasis. The extracellular matrix (ECM) also plays an important role in promoting invasive and metastatic potential of IDC. Specifically, the reorganization and alignment of collagen fibers in stromal ECM leads to directed tumor cell motility, which promotes metastasis. Lysyl oxidase like-2 (LOXL2) catalyzes ECM remodeling by crosslinking of collagen I in the ECM. We propose a novel mechanism whereby OSM induces LOXL2 expression, mediating stromal ECM remodeling of the breast TME.

methodsBioinformatics was utilized to determine survival and gene correlation in patients. IDC cell lines were treated with OSM (also IL-6, LIF, and IL-1β) and analyzed for LOXL2 expression by qRT-PCR and immunolabelling techniques. Collagen I contraction assays, 3D invasion assays, and confocal microscopy were performed with and without LOXL2 inhibition to determine the impact of OSM-induced LOXL2 on the ECM.

resultsOur studies demonstrate that IDC patients with high LOXL2 and OSM co-expression had worse rates of metastasis-free survival than those with high levels of either, individually, and LOXL2 expression is positively correlated to OSM/OSM receptor (OSMR) expression in IDC patients. Furthermore, human IDC cells treated with OSM resulted in a significant increase in LOXL2 mRNA, which led to upregulated protein expression of secreted, glycosylated, and enzymatically active LOXL2. The expression of LOXL2 in IDC cells did not affect OSM-promoted EMT, and LOXL2 was localized to the cytoplasm and/or secreted. OSM-induced LOXL2 promoted an increase in ECM collagen I fiber crosslinking, which led to significant fiber alignment between cells and increased IDC cell invasion.

conclusionsAligned collagen fibers in the ECM provide pathways for tumor cells to migrate more easily through the stroma to nearby vasculature and tissue. These results provide a new paradigm through which proinflammatory cytokine OSM promotes tumor progression. Understanding the nuances in IDC metastasis will lead to better potential therapeutics to combat against the possibility.

Indexed as

Amino Acid OxidoreductasesBreast NeoplasmsCarcinoma, Ductal, BreastCell Line, TumorCollagen Type IEpithelial-Mesenchymal TransitionExtracellular MatrixFemaleGlycosylationHumansInflammationNeoplasm MetastasisOncostatin MOncostatin M Receptor beta SubunitPrognosisSignal TransductionAmino Acid OxidoreductasesCollagen Type ILOXL2 protein, humanOncostatin MOncostatin M Receptor beta SubunitOSM protein, humanOSMR protein, humanBreast cancerCollagenCytokinesExtracellular matrixIL-6InflammationLOXL2MetastasisOSMTumor microenvironment

Identifiers

PMID34011405
PMCPMC8132418
OpenAlexW3161735103

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.